CIRM Funded Clinical Trials

A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease

Disease Area:
Immune Disease, Pediatrics, X-linked Chronic Granulomatous Disease
CIRM Grant:
CLIN2-08231 (Active)
Award Value:
Trial Stage:
Phase 1/2
Trial Status:
Targeted Enrollment:
16 ID:


X-linked Chronic Granulomatous Disease (X-CGD) is a rare immune disorder that prevents white blood cells from killing foreign invaders. This results in severe, recurrent infections that can impact quality and length of a patient’s life. X-CGD is usually diagnosed before age 5, but without treatment, children die before age 10. A team at UCLA is using the patient’s own genetically modified blood stem cells to create a new blood supply and a healthy immune system, with the aim of curing patients with this disease.


X-linked Chronic Granulomatous Disease.


Primary: Safety and Efficacy. Secondary: Restoration of immune function


Enrolling. Early evidence of clinical efficacy.

Contact Trial Sponsor

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website